Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| OMNICELL, INC.OMCL · Entity 4666 | EVP, Global R & D | March 11, 2019 | March 12, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
OMNICELL, INC.
Report date March 11, 2019 · Filed March 12, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 45,952 |
Reported balance
After 2019-03-11 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2019-03-11 · Exercise / conversion · Acquired 9,796 · Balance 45,952 |
| Common StockSEC Table I · non-derivative | Direct | 36,156 |
Reported balance
After 2019-03-11 transaction · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · 2019-03-11 · Sale · Disposed 9,796 · Balance 36,156 F1: The price reported in Column 4 is the average price of $83.9365. The sold price range between $83.60 to $84.00. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | Direct | 35,024 |
Reported balance
After 2019-03-12 transaction · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · 2019-03-12 · Sale · Disposed 1,132 · Balance 35,024 F2: The price reported in Column 4 is the exact price of $83.6763. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | Direct | 43,892 |
Reported balance
After 2019-03-12 transaction · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · 2019-03-12 · Exercise / conversion · Acquired 8,868 · Balance 43,892 |
| Common StockSEC Table I · non-derivative | Direct | 35,024 |
Reported balance
After 2019-03-12 transaction · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · 2019-03-12 · Sale · Disposed 8,868 · Balance 35,024 F3: The price reported in Column 4 is the average price of $83.7880. The sold price range between $83.25 to $84.02. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | Direct | 36,156 |
Reported balance
Holding disclosure · report date 2019-03-11 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 36,156 |
| Stock Options NQ (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.70 · Expires 2027-02-07 | Direct | 0 |
Reported balance
After 2019-03-11 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-03-11 · Exercise / conversion · Disposed 4,088 · Balance 0 |
| Stock Options NQ (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4,536.00 · Expires 2026-02-03 | Direct | 0 |
Reported balance
After 2019-03-11 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-03-11 · Exercise / conversion · Disposed 4,536 · Balance 0 |
| Stock Options NQ (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.02 · Expires 2025-02-05 | Direct | 0 |
Reported balance
After 2019-03-11 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-03-11 · Exercise / conversion · Disposed 1,172 · Balance 0 |
| Stock Options NQ (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.70 · Expires 2026-02-03 | Direct | 0 |
Reported balance
After 2019-03-12 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2019-03-12 · Exercise / conversion · Disposed 908 · Balance 0 |
| Stock Options NQ (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.70 · Expires 2027-02-07 | Direct | 0 |
Reported balance
After 2019-03-12 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2019-03-12 · Exercise / conversion · Disposed 628 · Balance 0 |
| Stock Options NQ (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.25 · Expires 2028-02-05 | Direct | 0 |
Reported balance
After 2019-03-12 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2019-03-12 · Exercise / conversion · Disposed 7,332 · Balance 0 |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is the average price of $83.9365. The sold price range between $83.60 to $84.00. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: The price reported in Column 4 is the exact price of $83.6763. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported in Column 4 is the average price of $83.7880. The sold price range between $83.25 to $84.02. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 15, 2017 Filed Jun 16, 2017 21:39 UTC | OMNICELL, INC. OMCL · Entity 4666 | Tax withholdingCommon Stock | 597 | $42.95 | $25,641.15 |
DisclosureSEC source: 0001179110-17-009221 · edgar.xml · nonDerivative · entry 3 Taborga Jorge R. · CIK 0001571822 · Executive VP. Engineering 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,270 F1 · shares: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 21:39 UTC | OMNICELL, INC. OMCL · Entity 4666 | Tax withholdingCommon Stock | 1,114 | $42.95 | $47,846.30 |
DisclosureSEC source: 0001179110-17-009221 · edgar.xml · nonDerivative · entry 2 Taborga Jorge R. · CIK 0001571822 · Executive VP. Engineering 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,867 F1 · shares: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| March 07, 2017 Filed Mar 9, 2017 22:14 UTC | OMNICELL, INC. OMCL · Entity 4666 | Tax withholdingCommon Stock | 1,157 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-004341 · edgar.xml · nonDerivative · entry 2 Taborga Jorge R. · CIK 0001571822 · Executive VP. Engineering 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,981 F1 · shares: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| February 08, 2017 Filed Feb 11, 2017 00:23 UTC | OMNICELL, INC. OMCL · Entity 4666 | GrantStock Option (right to Buy) · Derivative | 25,150 | $0.00 Strike: $36.70 | $0.00 |
DisclosureSEC source: 0001179110-17-002187 · edgar.xml · derivative · entry 4 Taborga Jorge R. · CIK 0001571822 · Executive VP. Engineering 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,150 Underlying: Common Stock · 25,150 shares Expires 2027-02-08 F2 · shares: Shares shall vest ratably over 48 month period, with a year cliff. Read SEC document |
| February 08, 2017 Filed Feb 11, 2017 00:23 UTC | OMNICELL, INC. OMCL · Entity 4666 | GrantCommon Stock | 10,220 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002187 · edgar.xml · nonDerivative · entry 3 Taborga Jorge R. · CIK 0001571822 · Executive VP. Engineering 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,138 F3 · shares: The Performance-based restricted stock unit awards vest as to 25% of the shares on the date of the Compensation Committee meeting in 2018 when the Committee reviews the performance-based metrics and determines if they were met or not with the remaining shares vesting on a semi-annual basis over a period of thirty-six months commencing on June 15, 2018 if the Company meets certain stock performance objectives compared to the NASDAQ Healthcare Index. The actual number of performance based stock awards that vest may be 0%, 50% or 100% of the numbers reflected above, depending upon the Company's performance. Read SEC document |
| February 08, 2017 Filed Feb 11, 2017 00:23 UTC | OMNICELL, INC. OMCL · Entity 4666 | GrantCommon Stock | 3,070 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002187 · edgar.xml · nonDerivative · entry 2 Taborga Jorge R. · CIK 0001571822 · Executive VP. Engineering 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,918 F1 · shares: Restricted Stock Units shall vest semiannually on 6/15 and 12/15 for a period of 4 years. Read SEC document |
| December 15, 2016 Filed Dec 16, 2016 22:43 UTC | OMNICELL, INC. OMCL · Entity 4666 | Tax withholdingCommon Stock | 2,307 | $33.90 | $78,207.30 |
DisclosureSEC source: 0001179110-16-033151 · edgar.xml · nonDerivative · entry 2 Taborga Jorge R. · CIK 0001571822 · Executive VP. Engineering 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,848 F1 · shares: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
| November 18, 2016 Filed Nov 18, 2016 23:36 UTC | OMNICELL, INC. OMCL · Entity 4666 | SaleCommon Stock | 2,068 | $33.66 | $69,599.99 |
DisclosureSEC source: 0001179110-16-031874 · edgar.xml · nonDerivative · entry 2 Taborga Jorge R. · CIK 0001571822 · Executive VP. Engineering 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,155 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold between $33.45 to $33.95. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote Read SEC document |
| September 15, 2016 Filed Sep 16, 2016 18:45 UTC | OMNICELL, INC. OMCL · Entity 4666 | Tax withholdingCommon Stock | 72 | $37.44 | $2,695.68 |
DisclosureSEC source: 0001179110-16-029700 · edgar.xml · nonDerivative · entry 2 Taborga Jorge R. · CIK 0001571822 · Executive VP. Engineering 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,223 F1 · shares: The sales reported in this Form 4 were mainly to cover tax withholding obligations in connection with the vesting of restricted stock units that occurred immediately prior to the date of sale. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.